The US government, as the dominant healthcare buyer through Medicare and Medicaid, has immense potential "monopsony" power to control prices. The central political conflict in healthcare will be how aggressively the public sector uses this leverage to squeeze providers and drug makers, balancing cost control against innovation incentives.

The Centers for Medicare & Medicaid (CMS) avoids cracking down on high-cost oncology drugs because they represent a critical profit center for otherwise low-margin hospitals. Hospitals lobby behind the scenes, arguing that reducing these reimbursements would create systemic issues in the healthcare system, creating a regulatory moat.

The US healthcare system rewards inefficiency, with multiple parties adding costs. Cash-pay systems bypass this, offering services and drugs at a lower net price by avoiding negotiations and markups inherent in the insurance-based model.

The US healthcare market suffers because massive, consolidated hospital systems and payers create negotiating "loggerheads." With no viable alternatives, they reach inefficient agreements where costs are inflated for everyone. A more fragmented market with smaller players would foster more genuine and effective price competition.

As the US population ages, more people enroll in Medicare, which typically under-reimburses hospitals for the full cost of care. To compensate for this revenue shortfall, hospitals raise the prices for patients with private, employer-sponsored insurance, effectively shifting costs from the public plan to commercial payers.

There is a profound mismatch between the critical role of diagnostics in guiding medical treatment and their reimbursement value. This value gap highlights a systemic inefficiency and a major opportunity for companies that can demonstrate improved patient outcomes and system-wide savings.

Official healthcare inflation appears lower than reality because hospitals are currently absorbing rising costs by accepting lower profit margins. This is not sustainable and suggests future price hikes as hospitals pass these costs on to insurers in upcoming negotiation cycles, which occur every two to three years.

Rather than lowering administrative overhead as expected, artificial intelligence is expanding private insurer reimbursements. Healthcare providers leverage AI systems to document clinical care more aggressively. This allows identical patient interactions to generate higher numbers of billing codes and produce greater profits for provider networks, contributing to rising healthcare costs rather than generating anticipated administrative savings.

The core driver of high insurance costs is the unregulated and widely variable prices charged for identical products and services. Different insurers pay vastly different amounts for the same thing, a market failure hidden from consumers by fixed co-pays, which ultimately leads to ever-increasing premiums for employers.